Joanne Salas1,2, Sarah Gebauer1,2, Auston Gillis1, Carissa van den Berk-Clark1, F David Schneider3, Paula P Schnurr4, Matthew J Friedman4, Sonya B Norman5, Peter W Tuerk6, Beth E Cohen7, Patrick J Lustman8,9, Jeffrey F Scherrer1,2. 1. Department of Family and Community Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA. 2. Harry S. Truman Veterans Administration Medical Center, Research Service, Columbia, MO, USA. 3. Department of Family and Community Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 4. National Center for PTSD and Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA. 5. National Center for PTSD and Department of Psychiatry, University of California San Diego, San Diego, CA, USA. 6. Sheila C. Johnson Center for Clinical Services, Department of Human Services, University of Virginia, Charlottesville, VA, USA. 7. Department of Medicine, University of California San Francisco School of Medicine and San Francisco VAMC, San Francisco, CA, USA. 8. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA. 9. The Bell Street Clinic Opioid Addiction Treatment Programs, VA St. Louis Healthcare System, St. Louis, MO, USA.
Abstract
INTRODUCTION: Improvement in posttraumatic stress disorder (PTSD) is associated with better health behavior such as better medication adherence and greater use of nutrition and weight loss programs. However, it is not known if reducing PTSD severity is associated with smoking cessation, a poor health behavior common in patients with PTSD. AIMS AND METHODS: Veterans Health Affairs (VHA) medical record data (2008-2015) were used to identify patients with PTSD diagnosed in specialty care. Clinically meaningful PTSD improvement was defined as ≥20 point PTSD Checklist (PCL) decrease from the first PCL ≥50 and the last available PCL within 12 months and at least 8 weeks later. The association between clinically meaningful PTSD improvement and smoking cessation within 2 years after baseline among 449 smokers was estimated in Cox proportional hazard models. Entropy balancing controlled for confounding. RESULTS: On average, patients were 39.4 (SD = 12.9) years of age, 86.6% were male and 71.5% were white. We observed clinically meaningful PTSD improvement in 19.8% of participants. Overall, 19.4% quit smoking in year 1 and 16.6% in year 2. More patients with versus without clinically meaningful PTSD improvement stopped smoking (n = 36, cumulative incidence = 40.5% vs. 111, cumulative incidence = 30.8%, respectively). After controlling for confounding, patients with versus without clinically meaningful PTSD improvement were more likely to stop smoking within 2 years (hazard ratio = 1.57; 95% confidence interval: 1.04-2.36). CONCLUSIONS: Patients with clinically meaningful PTSD improvement were significantly more likely to stop smoking. Further research should determine if targeted interventions are needed or whether improvement in PTSD symptoms is sufficient to enable smoking cessation. IMPLICATIONS: Patients with PTSD are more likely to develop chronic health conditions such as heart disease and diabetes. Poor health behaviors, including smoking, partly explain the risk for chronic disease in this patient population. Our results demonstrate that clinically meaningful PTSD improvement is followed by greater likelihood of smoking cessation. Thus, PTSD treatment may enable healthier behaviors and reduce risk for smoking-related disease.
INTRODUCTION: Improvement in posttraumatic stress disorder (PTSD) is associated with better health behavior such as better medication adherence and greater use of nutrition and weight loss programs. However, it is not known if reducing PTSD severity is associated with smoking cessation, a poor health behavior common in patients with PTSD. AIMS AND METHODS: Veterans Health Affairs (VHA) medical record data (2008-2015) were used to identify patients with PTSD diagnosed in specialty care. Clinically meaningful PTSD improvement was defined as ≥20 point PTSD Checklist (PCL) decrease from the first PCL ≥50 and the last available PCL within 12 months and at least 8 weeks later. The association between clinically meaningful PTSD improvement and smoking cessation within 2 years after baseline among 449 smokers was estimated in Cox proportional hazard models. Entropy balancing controlled for confounding. RESULTS: On average, patients were 39.4 (SD = 12.9) years of age, 86.6% were male and 71.5% were white. We observed clinically meaningful PTSD improvement in 19.8% of participants. Overall, 19.4% quit smoking in year 1 and 16.6% in year 2. More patients with versus without clinically meaningful PTSD improvement stopped smoking (n = 36, cumulative incidence = 40.5% vs. 111, cumulative incidence = 30.8%, respectively). After controlling for confounding, patients with versus without clinically meaningful PTSD improvement were more likely to stop smoking within 2 years (hazard ratio = 1.57; 95% confidence interval: 1.04-2.36). CONCLUSIONS: Patients with clinically meaningful PTSD improvement were significantly more likely to stop smoking. Further research should determine if targeted interventions are needed or whether improvement in PTSD symptoms is sufficient to enable smoking cessation. IMPLICATIONS: Patients with PTSD are more likely to develop chronic health conditions such as heart disease and diabetes. Poor health behaviors, including smoking, partly explain the risk for chronic disease in this patient population. Our results demonstrate that clinically meaningful PTSD improvement is followed by greater likelihood of smoking cessation. Thus, PTSD treatment may enable healthier behaviors and reduce risk for smoking-related disease.
Authors: Jodie B Greenberg; Katherine J Ameringer; Michael A Trujillo; Ping Sun; Steve Sussman; Molly Brightman; Stephanie R Pitts; Adam M Leventhal Journal: Psychol Addict Behav Date: 2011-06-20
Authors: Sandra Baker Morissette; Matthew T Tull; Suzy Bird Gulliver; Barbara Wolfsdorf Kamholz; Rose T Zimering Journal: Psychol Bull Date: 2007-03 Impact factor: 17.737
Authors: Jeffrey F Scherrer; Joanne Salas; Sonya B Norman; Paula P Schnurr; Kathleen M Chard; Peter Tuerk; F David Schneider; Carissa van den Berk-Clark; Beth E Cohen; Matthew J Friedman; Patrick J Lustman Journal: JAMA Psychiatry Date: 2019-11-01 Impact factor: 21.596
Authors: A C Kirby; B P Hertzberg; C F Collie; B Yeatts; M F Dennis; S D McDonald; P S Calhoun; J C Beckham Journal: Addict Behav Date: 2008-05-22 Impact factor: 3.913
Authors: Joanne Salas; Jeffrey F Scherrer; Peter Tuerk; Carissa van den Berk-Clark; Kathleen M Chard; F David Schneider; Paula P Schnurr; Matthew J Friedman; Sonya B Norman; Beth E Cohen; Patrick Lustman Journal: J Affect Disord Date: 2019-08-31 Impact factor: 4.839
Authors: Jeffrey F Scherrer; Joanne Salas; Kathleen M Chard; Peter Tuerk; Carissa van den Berk-Clark; F David Schneider; Beth E Cohen; Patrick J Lustman; Paula P Schnurr; Matthew J Friedman; Sonya B Norman Journal: J Psychosom Res Date: 2019-10-15 Impact factor: 3.006
Authors: Joanne Salas; Sonya B Norman; Peter W Tuerk; Carissa van den Berk-Clark; Beth E Cohen; F David Schneider; Kathleen M Chard; Patrick J Lustman; Paula P Schnurr; Matthew J Friedman; Richard Grucza; Jeffrey F Scherrer Journal: Drug Alcohol Depend Date: 2020-10-18 Impact factor: 4.492